

# Caladrius Biosciences, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

<https://marketpublishers.com/r/N1359DC931ABEN.html>

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: N1359DC931ABEN

## Abstracts

Caladrius Biosciences, Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Caladrius Biosciences, Inc. and its competitors. This provides our Clients with a clear understanding of Caladrius Biosciences, Inc. position in the [Pharmaceuticals and Biotechnology](#) Industry.

The report contains detailed information about Caladrius Biosciences, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Caladrius Biosciences, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Caladrius Biosciences, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios

pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Caladrius Biosciences, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Caladrius Biosciences, Inc. business.

### **About Caladrius Biosciences, Inc.**

NeoStem, Inc. provides adult stem cell collection, processing, and storage services enabling healthy individuals to donate and store their stem cells for personal therapeutic use in the United States. It also engages in pharmaceuticals business in China.

#### **Adult Stem Cell Business in the U.S.**

The company is developing its business in the adult stem cell field to capitalize on the importance that adult stem cells may have in regenerative medicine, with an initial focus on the delivery of therapies for cardiac, orthopedic, wound, cosmetic, and dermatologic indications.

#### **Collection, Processing, and Storage Services**

The company provides adult stem cell collection, processing, and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use. The company's network of U.S. adult stem cell collection centers is primarily focused on the southern California and Northeast markets.

## VSEL Technology and Other Therapeutic Technologies

The company is engaged in research and development of new therapies based on very small embryonic-like stem cells (the VSEL technology) with the University of Louisville Research Foundation (ULRF) and has a worldwide license to the VSEL technology.

## Adult Stem Cell Business in China

The company's stem cell-based initiatives in China include developing a pipeline of regenerative medicine therapies, initially focused on orthopedic conditions; developing wellness, cosmetic and anti-aging applications; participating in the medical tourism market for regenerative medical treatments; establishing a network of collection, processing and storage facilities; and engaging in research and development designed to improve and expand its service and product offerings both in the U.S. and in China.

## Orthopedic Therapies

In March 2009, the company acquired a license for Asia to use a process that expands a patient's own adult stem cells to treat various musculoskeletal diseases. The licensed procedure, Regenexx, has been developed by a Colorado-based company, Regenerative Sciences, Inc. (RSI). The Regenexx procedure uses autologous mesenchymal stem cells extracted from bone marrow for the treatment of various orthopedic conditions, including osteoarthritis, meniscus tears of the knee, avascular necrosis and bulging lumbar discs. In addition, its agreement with RSI includes consulting services to be provided by RSI to it in the area of stem cell-based orthopedic therapies for the Asia market.

## Wellness, Cosmetic & Anti-Aging Applications

The company is developing a program that includes products and therapies, including stem cell-based therapies and health supplements that it intends to offer for wellness, cosmetic and anti-aging applications.

## Pharmaceutical Business in China — Suzhou Erye Pharmaceuticals Company Ltd. (Erye)

Erye focuses primarily on the manufacturing and sale of antibiotics. Erye has concentrated its efforts on the manufacturing and distribution of generic antibiotic products and has received approximately 160 production certificates covering both

antibiotic prescription drugs and active pharmaceutical intermediates (APIs). Erye offers a portfolio of anti-infective drugs, including Acetylspiramycin and Oxacillin Sodium, which are APIs; and Mezlocillin Sodium, Amoxicillin/Sulbactam Sodium, and Cefoperazone/Sulbactam Sodium, which are injectible finished products.

### Strategic Alliances

On April 22, 2010, the company and ImmuneRegen BioSciences, Inc. have entered into a collaborative research agreement, focused on the development of an advanced, adult human stem cell product.

On May 05, 2010, Neostem, Inc. announced that collaborative agreement with Enhance Biomedical Holding Corporation for the development of an adult stem cell collection and treatment network in Taiwan and Shanghai, as well as the Chinese provinces of Jiangsu, Zhejiang, Fujian, Anhui, and Jiangxi.

### Competition

The company's direct competitors are domestic pharmaceutical companies and new drug research and development institutes, such as Harbin Pharmaceutical Group Holding Co., Ltd.; Shanghai Asia Pioneer Pharmaceutical Co., Ltd; Shandong Lukang Pharmaceutical Co., Ltd.; Shandong Luoxin Pharmacy Stock Co. Ltd.; China Pharma Holdings; China Biologic Products; China Sky One Medical; Sinovac Biotech; and Tianyin Pharma. It also identifies competition from Beike Biotechnology Co Ltd. in China.

### History

NeoStem, Inc. was founded in 1980.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Contents

RESEARCH METHODOLOGY

DISCLAIMER

### **1. CALADRIUS BIOSCIENCES, INC. COMPANY PROFILE**

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

### **2. CALADRIUS BIOSCIENCES, INC. BUSINESS OVERVIEW**

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

### **3. CALADRIUS BIOSCIENCES, INC. SWOT ANALYSIS**

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

### **4. CALADRIUS BIOSCIENCES, INC. FINANCIAL ANALYSIS**

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. CALADRIUS BIOSCIENCES, INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Caladrius Biosciences, Inc. Direct Competitors
- 5.2. Comparison of Caladrius Biosciences, Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Caladrius Biosciences, Inc. and Direct Competitors Stock Charts
- 5.4. Caladrius Biosciences, Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Caladrius Biosciences, Inc. Industry Position Analysis

## **6. CALADRIUS BIOSCIENCES, INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. CALADRIUS BIOSCIENCES, INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Consensus
- 7.2. Experts Revisions

## **8. CALADRIUS BIOSCIENCES, INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. CALADRIUS BIOSCIENCES, INC. IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. CALADRIUS BIOSCIENCES, INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. CALADRIUS BIOSCIENCES, INC. VRIO ANALYSIS<sup>2</sup>**

### **APPENDIX: RATIO DEFINITIONS**

### **LIST OF FIGURES**

Caladrius Biosciences, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit  
Profit Margin Chart  
Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
Caladrius Biosciences, Inc. 1-year Stock Charts  
Caladrius Biosciences, Inc. 5-year Stock Charts  
Caladrius Biosciences, Inc. vs. Main Indexes 1-year Stock Chart  
Caladrius Biosciences, Inc. vs. Direct Competitors 1-year Stock Charts  
Caladrius Biosciences, Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.  
The complete financial data is available for publicly traded companies.

## List Of Tables

### LIST OF TABLES

Caladrius Biosciences, Inc. Key Facts  
Profitability  
Management Effectiveness  
Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
Caladrius Biosciences, Inc. Key Executives  
Caladrius Biosciences, Inc. Major Shareholders  
Caladrius Biosciences, Inc. History  
Caladrius Biosciences, Inc. Products  
Revenues by Segment  
Revenues by Region  
Caladrius Biosciences, Inc. Offices and Representations  
Caladrius Biosciences, Inc. SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
Caladrius Biosciences, Inc. Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
Caladrius Biosciences, Inc. Capital Market Snapshot  
Caladrius Biosciences, Inc. Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics

Caladrius Biosciences, Inc. Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Caladrius Biosciences, Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## ANALYSIS FEATURES

### SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

### Enhanced SWOT Analysis

Enhanced SWOT is a 3x3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

### PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

### Key Factors Examined by PESTEL Analysis:

**Political** – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

**Economic** – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

**Sociological** – What cultural and societal aspects will work upon the demand for the business's products and operations?

**Technological** – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

**Environmental** – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

**Legal** – What laws and legislation will exert influence on the style the business is carried out?

### **IFE, EFE, IE Matrices**

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors

integrated into one suggestive model.

## **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

## **VRIO Analysis**

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity

## Reputation

### Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?

## I would like to order

Product name: Caladrius Biosciences, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: <https://marketpublishers.com/r/N1359DC931ABEN.html>

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N1359DC931ABEN.html>